Glutamate Neurotoxicity in Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000010
Summary
Dr. Ayoub is exploring the role of the signaling molecule glutamate, acting through NMDA receptors, in retinal ganglion cell death. He has hypothesized that, under the high IOP conditions found in glaucoma, glutamate is released continuously. This would be an important finding if true because the prolonged presence of glutamate can be toxic to nerve cells and stimulate cell death. Dr. Ayoub is measuring glutamate and analyzing its effects on ganglion cell survival to determine the amount of glutamate that is sufficient to cause cell death. In addition, the neuroprotective action of cannabinoids is being analyzed to determine if they can suppress glutamate levels and/or suppress cell death. Dr. Ayoub has already determined the level of glutamate needed to cause neurotoxicity, and has refined his experimental approach accordingly. Clinical trials are now taking place elsewhere to determine the effects of glutamate suppressors in glaucoma, so the results of this study could prove timely.
Related Grants
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
National Glaucoma Research
Mitochondria in Retinal Ganglion Cells
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Rob Nickells, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
W. Daniel Stamer, PhD
Current Organization
Duke University